Astra profits plunge by third
AstraZeneca’s new boss faced a double-headache today as pre-tax profit tumbled by more than a third to $1.3 billion (£840 million) in the first quarter and a pay revolt loomed at his first AGM.
Pascal Soriot, who joined from Roche last October, had little good news for investors who met at the Lancaster Gate hotel today, just hours after AstraZeneca admitted that sales were down 13% to $6.4 billion in the first three months of this year. Pre-tax profit slumped 36%. The figures were worse than the City’s low expectations and because certain medicines — including antipsychotic drug Seroquel — had fallen out of patent, facing generic competition without any new big-sellers replacing them. Soriot last month outlined a new strategy which includes axing nearly 4000 jobs — including hundreds in the UK — and streamlining research and development to focus on a few areas, such as cancer.
But the AGM was his first time facing investors and it was set to be uncomfortable, as a significant group of investors have been advised to reject his pay plans.
Soriot is due to receive £6.5 million for just three months’ work, including a £991,000 “golden hello” to compensate him for his forfeited bonus from his previous employer, and £2 million in restricted shares and in ordinary shares, subject to performance.
Former boss David Brennan, who quit after pressure from angry shareholders, was also awarded £4.9 million for six months’ work. But the Local Authority Pension Fund Forum, the biggest group of public-sector pension funds which runs £115 billion of assets, has recommended its members oppose Astra’s remuneration report.
Investors are concerned at the big payout at a time when drugs that account for more than 40% of sales at Britain’s second-biggest drugmaker expire by the end of next year.
First-quarter sales of Brilinta — a heart drug which AstraZeneca had hoped to become a blockbuster — rose only modestly in the quarter, bringing in $51 million rather than $38 million in the last quarter of 2012.
Soriot told investors: “We remain focused on our strategic priorities of returning to growth and achieving scientific leadership.” But he admitted this year sales are expected to fall by a “mid- to high-single-digit percentage”.
- 1 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 2 Russian girl takes her own life after parents find pornography on her computer
- 4 Ball pool for adults opens in London
- 5 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
Russian girl takes her own life after parents find pornography on her computer
Kim Kardashian on Bruce Jenner's 'story': 'We support him no matter what, and I think when the time is right, he'll talk'
Michelle Obama highlights harsh restrictions faced by Saudi women after meeting King Salman without wearing a headscarf
Ball pool for adults opens in London
Amal Clooney gives excellent response to fashion question at European Court of Human Rights
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Greece elections: Syriza and EU on collision course after election win for left-wing party
Have we reached 'peak food'? Shortages loom as global production rates slow
British Muslim school children suffering a backlash of abuse following Paris attacks
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
iJobs Money & Business
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...
Competitive salary & benefits!: MBDA UK Ltd: MBDA UK LTD Indirect Procurement...